Abstract
A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.
MeSH terms
-
BRCA1 Protein / genetics
-
BRCA2 Protein / genetics
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics
-
Breast Neoplasms / pathology
-
Clinical Trials, Phase II as Topic
-
Drug-Related Side Effects and Adverse Reactions
-
Female
-
Humans
-
Male
-
Mutation
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / pathology
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / pathology
-
Phthalazines / therapeutic use*
-
Piperazines / therapeutic use*
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / pathology
Substances
-
BRCA1 Protein
-
BRCA1 protein, human
-
BRCA2 Protein
-
BRCA2 protein, human
-
Phthalazines
-
Piperazines
-
olaparib